Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Dare Bioscience (DARE) EBITDA Margin (2016 - 2025)

Dare Bioscience's EBITDA Margin history spans 6 years, with the latest figure at 143.34% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 889879.0% year-over-year to 143.34%; the TTM value through Dec 2025 reached 1299.96%, up 4082506.0%, while the annual FY2025 figure was 1299.96%, 4082506.0% up from the prior year.
  • EBITDA Margin reached 143.34% in Q4 2025 per DARE's latest filing, up from 157201.86% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 57604.15% in Q2 2024 to a low of 157201.86% in Q3 2025.
  • Average EBITDA Margin over 4 years is 15874.3%, with a median of 276.51% recorded in 2023.
  • The largest YoY upside for EBITDA Margin was 5587668bps in 2025 against a maximum downside of -14597745bps in 2025.
  • A 4-year view of EBITDA Margin shows it stood at 2.78% in 2022, then plummeted by -10042bps to 276.51% in 2023, then surged by 3266bps to 8755.45% in 2024, then crashed by -102bps to 143.34% in 2025.
  • Per Business Quant, the three most recent readings for DARE's EBITDA Margin are 143.34% (Q4 2025), 157201.86% (Q3 2025), and 18909.83% (Q2 2025).